BRIEF-FDA Says Teligent Pharma, Inc.’S Issues Voluntary Recall Of Lidocaine Hcl Topical Solution 4% (Lot # 14218, Exp. 09/2022) Due To Super Potency

Reuters
31 Aug 2021

Aug 30 (Reuters) - U.S. FDA:

* TELIGENT PHARMA, INC.’S ISSUES VOLUNTARY RECALL OF LIDOCAINE HCL TOPICAL SOLUTION 4% (LOT # 14218, EXP. 09/2022) DUE TO SUPER POTENCY

* FDA SAYS TO DATE, TELIGENT PHARMA, HAS NOT RECEIVED ANY REPORTS OF ADVERSE EVENTS RELATED TO RECALL

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10